Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Advanced Renal Cell Carcinoma Clinical Trials

Review the advanced renal cell carcinoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 49

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Status: Active
Location: 44 locations
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
Status: Active
Location: 15 locations
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 13 locations
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Status: Active
Location: 11 locations
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma that has Spread to the Brain
Status: Active
Location: 7 locations
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations
Lattice Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Status: Active
Location: 7 locations
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Status: Active
Location: 6 locations
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Status: Active
Location: 6 locations
Alternate Cabozantinib Dosing Schedule Alone and in Combination with Nivolumab for the Treatment of Metastatic Kidney Cancer and Neuroendocrine Tumors
Status: Active
Location: 5 locations
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Status: Active
Location: 3 locations
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: 3 locations
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Status: Active
Location: 4 locations
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Status: Active
Location: 4 locations
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: 3 locations
177Lu-PSMA-617 for the Treatment of Advanced Clear Cell Renal Cell Carcinoma, LASER Trial
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
ALG.APV-527 First-in-human Study
Status: Active
Location: 2 locations
Stereotactic Body Radiation Therapy with Nivolumab and BMS986253 for the Treatment of Multiple Metastases in Patients with Advanced Solid Tumors
Status: Active
Location: 2 locations
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
Cytokine Induced Memory-Like Natural Killer Cells in Combination with Aldesleukin for the Treatment of Locally Advanced or Metastatic Renal Cell Cancer or Urothelial Cancer
Status: Active
Location: 2 locations
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
XL092 with or without Nivolumab for the Treatment of Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York